Shares of XBiotech Inc. (NASDAQ:XBIT) traded down 1.6% during mid-day trading on Tuesday . The stock traded as low as $12.82 and last traded at $12.98, with a volume of 88,206 shares trading hands. The stock had previously closed at $13.19.

Several analysts have issued reports on the company. Noble Financial restated a “buy” rating and set a $24.00 price objective on shares of XBiotech in a research note on Thursday, May 19th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Tuesday, May 24th.

The stock’s 50 day moving average is $14.90 and its 200 day moving average is $13.32. The stock’s market cap is $422.72 million.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.